about
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted TherapiesBone regeneration and stem cellsIn vitro testing of the potential for orthopedic bone cements to cause apoptosis of osteoblast-like cells.Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate.A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate.Is wear debris responsible for failure in alumina-on-alumina implants?Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Networks in CancerDo ion levels in hip resurfacing differ from metal-on-metal THA at midterm?Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD.Idiopathic and secondary osteonecrosis of the femoral head show different thrombophilic changes and normal or higher levels of platelet growth factors.Enhancing osteoconduction of PLLA-based nanocomposite scaffolds for bone regeneration using different biomimetic signals to MSCs.Ex vivo observation of human intervertebral disc tissue and cells isolated from degenerated intervertebral discsIdentification and Validation of Housekeeping Genes for Gene Expression Analysis of Cancer Stem Cells.Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA speciesTumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion.Hypoxia enhances proliferation and stemness of human adipose-derived mesenchymal stem cellsHistogenetic characterization of giant cell tumor of boneDoes ion release differ between hip resurfacing and metal-on-metal THA?Do ion levels in metal-on-metal hip resurfacing differ from those in metal-on-metal THA at long-term followup?Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bedAltered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.In vitro models for the evaluation of angiogenic potential in bone engineering.Orthopaedic research in italy: state of the art.The combined use of mesenchymal stromal cells and scaffolds for bone repair.In vitro evaluation of freeze-dried bone allografts combined with platelet rich plasma and human bone marrow stromal cells for tissue engineering.MicroRNA expression profiling of human bone marrow mesenchymal stem cells during osteogenic differentiation reveals Osterix regulation by miR-31.Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.Gene expression patterns related to osteogenic differentiation of bone marrow-derived mesenchymal stem cells during ex vivo expansion.Potassium citrate prevents increased osteoclastogenesis resulting from acidic conditions: Implication for the treatment of postmenopausal bone loss.Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation.Multimodal transfer of MDR by exosomes in human osteosarcoma.Energy metabolism in osteoclast formation and activity.Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells.Carbonic anhydrase IX inhibition is an effective strategy for osteosarcoma treatment.The effect of extracellular acidosis on the behaviour of mesenchymal stem cells in vitro.Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered laminsMesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells.Treatment for long bone metastases based on a systematic literature review.
P50
Q26745742-B25A8E2C-3320-49D8-B18E-4B0E69CB95C3Q28659195-0D02C223-DD3B-4D52-9CD5-0C9AE224201DQ33183217-C9E02AC6-22BE-4BC5-BFED-3044CDDF2CECQ33314463-061A0D9C-FFE1-4634-9C4C-1309755B39D0Q33405612-5B264EC0-4A47-41F6-824C-C7F31C513204Q33659834-AB420CB7-FD8B-4798-B034-FCDB895BD42AQ33869480-E73CC8DE-80A2-465D-94F2-D3BA3CEB8D21Q34434934-F1E114F7-0B71-4772-A790-0F0562B35E6FQ35348175-0E9A9336-725C-40A5-B653-F2F84D41D7F6Q35590540-AB44793D-DD45-4E26-BC6B-23145A33F7F8Q35795933-E85E6734-E5F3-4A14-A646-A66D776C2A97Q35886192-086DC7B6-EFAC-4194-AAC8-58E6FEDBA3EBQ35928531-722DC8FB-40A9-4AD6-A930-3CBA4CD63BBAQ35930111-CD029147-461B-4C1E-BCCE-CC0EBCFCFA87Q36194212-DD4FA6C5-AC14-4481-8F21-184F7F59BCCEQ36237006-07ED2142-596D-4ADE-A46D-14E2EEDF742EQ36803589-64C77B09-8F8B-4B86-82B0-CC65D75562B2Q36826142-2887776E-440C-42E5-BAD6-F628DEFEAEC4Q37072363-154A0CE7-4367-48DD-9397-190E0D5755DDQ37273398-C948BA4F-1BE9-45C6-B02A-435A27EB25EFQ37665338-CB05EC0A-8A19-4BD1-B114-D5504E32D6CBQ37806059-651CBFBC-76FB-4740-AE24-188CD882B4B2Q37888852-C57E534F-C7ED-4D01-9B47-C52291C98C22Q37986803-80C99958-5CEF-4060-9F8D-0813F4B4F04BQ38288766-9F2CE6A8-6343-4B9C-BEF5-89BBB79230ACQ38314373-D65E04F6-8F08-4E3E-8895-9D31B06B9B06Q38478426-0F67F999-3614-4919-87D6-1BC6E70973AFQ38509223-8D5A8BC8-DBE8-4531-AC9A-53E0BBA17BBDQ38675617-2A0F95FF-29AB-4E24-9023-86F6109E214FQ38728887-76B9AF2A-B521-4121-95FC-3E0CC1B90778Q38771225-B2F9A0D1-66C8-48C1-B642-E1DE237C1BBCQ38824770-0C19B385-7AED-4208-A608-1B66D6D9BE8BQ38834656-6E4AEF23-9C7B-43DB-9634-8F49575A14A7Q38836322-4DF7CACA-93DA-49CE-A221-BB6EBA3623A8Q38861110-B86B70C8-B357-40F6-BD6B-A16DFCD22A6BQ38883199-0A1CE85E-9A7D-47FB-9EA9-4C01B0EC187DQ38893099-974E55C2-AA91-47AF-A00B-6B10A88287ADQ38938230-8743078D-EACF-483E-97B4-7132DDB6CF6DQ38951141-2BBEB837-AA91-4EC0-B0B0-E0414F58DD65Q38960060-56BCD584-8A40-49C5-8405-B22A789B3260
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Baldini
@ast
Nicola Baldini
@en
Nicola Baldini
@es
Nicola Baldini
@nl
Nicola Baldini
@sl
type
label
Nicola Baldini
@ast
Nicola Baldini
@en
Nicola Baldini
@es
Nicola Baldini
@nl
Nicola Baldini
@sl
prefLabel
Nicola Baldini
@ast
Nicola Baldini
@en
Nicola Baldini
@es
Nicola Baldini
@nl
Nicola Baldini
@sl
P1053
J-4806-2016
P106
P1153
7006625138
P21
P31
P3829
P496
0000-0003-2228-3833